Skip to content
Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

NEW KIND OF ANTIBIOTIC KILLS GERMS & BOOSTS IMMUNITY

The growing army of bacteria able to resist conventional antibiotics is one of the top ten threats to human health, according to the World Health Organization, and, by 2050, will kill ten million people a year and drain $100 million annually from the global economy.
But not if researchers at Pennsylvania’s Wistar Institute can help it.
The research group has concocted a new family of antibiotics that kills a wide range of pathogens while boosting the human immune system’s strength.
A bacterium becomes drug-resistant by mutating the portions of its cell surface that an antibiotic targets.
The research group dove deeper, targeting a cellular process that makes enzymes crucial for almost all dangerous bacteria’s survival but is absent from human cells.
The team used a computer to sort through millions of commercially available substances and rate their ability to bind the enzyme; then the scientists used the most promising of those as starting points to design drugs for the task.
The resulting drugs not only were effective in neutralizing the bacteria’s essential enzyme but also stimulated human immune responses at the same time, giving the drugs double capacity: killing bacteria and making immune responses more powerful at the same time.
TRENDPOST: Wistar’s breakthrough does more than hint at a solution to the pandemic of antibiotic resistance. It also is among the first pharmaceuticals to unite the power of a drug with that of the human immune system in a single compound.

Comments are closed.